M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals

Figure 1 Correlation between serum Mac-2 binding protein glycosylation isomer levels and liver stiffness measurement at baseline and after patients achieved sustained virologic response 12. A: Correlation between serum Mac-2 binding protein glycosylation isomer (M2BPGi) levels and liver stiffness measurement (LSM) at baseline; B: Correlation between serum M2BPGi levels and LSM After patients achieved sustained virologic response 12. M2BPGi: Mac-2 binding protein glycosylation isomer; LSM: Liver stiffness measurement; SVR: Sustained virologic response.

Figure 2 Diagnostic performance of non-invasive parameters in differentiating grades F4 from F0-3 at baseline and after patients achieved sustained virologic response 12. A: Diagnostic performance of non-invasive parameters in differentiating grades F4 from F0-3 at baseline; B: Diagnostic performance of non-invasive parameters in differentiating grades F4 from F0-3 after patients achieved sustained virologic response 12. FIB-4: Fibrosis-4; M2BPGi: Mac-2 binding protein glycosylation isomer.

Figure 3 Diagnostic performance of non-invasive parameters in differentiating grades F3-4 from F0-2 at baseline and after patients achieved sustained virologic response 12. A: Diagnostic performance of non-invasive parameters in differentiating grades F3-4 from F0-2 at baseline; B: Diagnostic performance of non-invasive parameters in differentiating grades F3-4 from F0-2 After patients achieved sustained virologic response 12. FIB-4: Fibrosis-4; M2BPGi: Mac-2 binding protein glycosylation isomer.